International Journal of Clinical Research

Objective To study and analyze the value of Rebaptiste combined with esomeprazole in patients with chronic erosive gastritis. Methods 60 patients with chronic erosive gastritis admitted to our hospital from September 2021 to September 2023 were randomly divided into study group and control group, with 30 cases in each group. Patients in both groups received conventional treatment for chronic erosive gastritis, the control group was given esomeprazole, and the study group was given Rebaptiste combined with esomeprazole for continuous treatment for 2 weeks. The therapeutic effect and serum factor levels before and after treatment were evaluated and compared between the two groups. Results After treatment, the total effective rate of the study group was higher than that of the control group, and the levels of tumor necrosis factor-α, interleukin-6, interleukin-8 and other serum factors were lower than those of the control group, with statistical significance (P < 0.05). Conclusion In the treatment of chronic erosive gastritis, the combination of Rebabapide and esomeprazole is of great value in improving the curative effect and serum factor level.

Chronic erosive gastritis; Rebabapide; Esomeprazole; Curative effect; Serum factor